The FDA has approved Fragmin, a low molecular weight heparin, for the treatment of symptomatic venous thromboembolism to reduce the recurrence of VTE in pediatric patients 1 month of age and older.
DUBLIN--(BUSINESS WIRE)--The "Prefilled Syringes - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Prefilled Syringes was estimated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results